Drug product formulation development, GMP manufacture, and long-term stability studies of bitox for phase i clinical trials
Ended Awarded Last action
- Contract number
- 75N91023F00021
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,649,757
Award facts
- Contract value 100% obligated
- $1,649,757.00 Current and potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Award Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $1,649,757 |
About this award
The National Center for Advancing Translational Sciences issued a delivery order to Leidos Biomedical Research Inc. on September 15, 2023, with a ceiling value of $1,649,757.00 for drug product formulation development, GMP manufacture, and long-term stability studies of Bitox and chitosan-conjugated nanoparticle candidates for Phase I clinical trials.
Place of performance is Frederick, Maryland. The order extends to September 14, 2028. Pricing is cost-plus-award-fee. This is a delivery order against a parent indefinite delivery vehicle (parent vehicle details are not identified in the source).
Service Contract Inventory reporting shows the order invoiced $42 thousand in FY2023, $6 thousand in FY2024 (88 contractor hours at $63.22/hr, 0.0 FTEs), and $160 thousand in FY2025 (0.6 FTEs). In FY2025, the prime self-performed all reported hours with no subcontractors engaged. Leidos Biomedical Research is a subsidiary of Leidos Holdings Inc. and operates the Frederick National Laboratory for Cancer Research on behalf of the National Cancer Institute as an FFRDC contractor.
Quick answers
Who was awarded contract 75N91023F00021?
75N91023F00021 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 15, 2023.
How much is contract 75N91023F00021 worth?
The government has obligated $1,649,757 on 75N91023F00021.
Which agency awarded contract 75N91023F00021?
National Cancer Institute (National Institutes of Health) awarded 75N91023F00021, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Is contract 75N91023F00021 an order under another contract?
Yes. 75N91023F00021 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91023F00021 competed?
The extent of competition for 75N91023F00021 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award